References
- Rose C, Thorpe S M, Anderson K W, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1: 16–23
- Allegra J C, Lippman M E, Thompson E B, et al. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer 1980; 16: 323–331
- Allegra J C, Barlock A, Huff K K, et al. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 1980; 45: 792–794
- Sherwin S A, Mayer D, Ochs J J, et al. Recombinant leucocyte in-terferon in advanced breast cancer. Ann Intern Med 1983; 99: 598–602
- Borden E C, Holland J F, Dao T L, et al. Leucocyte derived inter-feron alpha in human breast carcinoma. Ann Intern Med 1982; 27: 1–6
- Nethersell A, Smedley H, Katrak M, et al. Recombinant interferon in advanced breast cancer. Br J Cancer 1984; 49: 615–20
- Bezwoda W R, Meyer K. Effect of alpha-interferon, 17 beta-estradiol and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res 1990; 50: 5387–5391
- Seymour L, Bezwoda W R. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer 1993; 68: 353–356
- Hayward J L, Carbone P P, Heuson J C, et al. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289–1294
- Andersen J, Poulsen H S. Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol 1988; 27: 761–765
- Van den Berg H W, Leakey W J, Lynch M, et al. Recombinant human interferon alpha increases estrogen, receptor expression in human breast cancer cells (ZR-75–1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br 3 Cancer 1987; 55: 255–257
- Sica G, Natoli V, Stella C, et al. Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 1987; 60: 2419–2423
- Pouillart P, Palangie T, Jouve M, et al. Administration of fibro-blast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol 1982; 18: 929–935
- Macheledt J E, Buzdar A U, Hortobagyi G N, et al. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treatm 1991; 18: 165–170
- Marth C H, Mayer I, Boch G, . Effects of human interferon alpha-2 and gamma on proliferation, estrogen receptor content, and sensitivity to anti-estrogens of cultured breast cancer cells. The Interferon System, F Dianzahl, G H Dianzahl, et al. Raven Press, New York 1985; 367–371
- Kauppila A, Centell K, Janne O, et al. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int J Cancer 1982; 29: 291–294
- Porzsolt F, Otto A M, Trauschel B, et al. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol 1989; 115: 465–469
- Crawford D J, Cowan S, Fitch R, et al. Stability of estrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 1987; 56: 137–144
- Nomura Y, Tashiro H, Shinozuka K. Changes of steroid hormone content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 1985; 55: 546–552